Sanofi's Venglustat Fails to Show Efficacy in Phase 2 Trial for GBA1-Associated Parkinson’s Disease, Published in The Lancet Neurology

Recently, researchers from Sanofi S.A. published an article in "The Lancet》Sub-journal The Lancet Neurology published a research paper titled: Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Parkinson's disease is not a single-gene disorder, but there are many significant genetic variations associated with an increased risk of Parkinson's disease. Mutations in the GBA1 gene are highly correlated with Parkinson's disease. This study represents the first truly personalized therapy for Parkinson's disease. In this international, multicenter, double-blind, randomized, placebo-controlled Phase 2 clinical trial, venglustat failed to demonstrate therapeutic efficacy in patients with GBA1 mutation-associated Parkinson's disease.

In this Phase 2 clinical trial, 221 Parkinson's disease patients with GBA1 gene mutations from 52 medical centers worldwide received either weekly ventlustat or a placebo for one year. The results showed that ventlustat was safe with only mild side effects but did not demonstrate therapeutic benefits for Parkinson's disease patients.

The research team stated that the drug did indeed reduce the levels of glucosylceramide synthase (GCS), but the ultimate therapeutic effect was recessive. This clinicalStudy DesignAnd the execution was very good, but the drug did not play a therapeutic role, indicating that inhibiting glucosylceramide synthase (GCS) may not be a way to treat Parkinson's disease caused by GBA1 gene mutations. However, this does not negate the association between GBA1 gene mutations and Parkinson's disease. In the future, it may be possible to attempt treating the disease by targeting GBA1 through other means.